Literature DB >> 27372879

Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders.

Navya Lakkappa1, Praveen T Krishnamurthy2, Bruce D Hammock3, D Velmurugan4, M M Srinivas Bharath5.   

Abstract

Parkinson's disease (PD) is a multifactorial neurodegenerative disease involving oxidative stress, neuroinflammation and apoptosis. Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites and they play a role in cytoprotection by modulating various cell signaling pathways. This cytoprotective role of EETs are well established in cerebral stroke, cardiac failure, and hypertension, and it is due to their ability to attenuate oxidative stress, endoplasmic reticulum stress, inflammation, caspase activation and apoptosis. The actions of EETs in brain closely parallel the effects which is observed in the peripheral tissues. Since many of these effects could potentially contribute to neuroprotection, EETs are, therefore, one of the potential therapeutic candidates in PD. Therefore, by increasing the half life of endogenous EETs in vivo via inhibition of sEH, its metabolizing enzyme can, therefore, constitutes an important therapeutic strategy in PD.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cytochrome P450; EETs; Neuroinflammation; Neuroprotection; Oxidative stress; PD; sEH

Mesh:

Substances:

Year:  2016        PMID: 27372879      PMCID: PMC4985172          DOI: 10.1016/j.mehy.2016.06.003

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  67 in total

Review 1.  Pathophysiology of Parkinson's disease.

Authors:  A M Bonnet; J L Houeto
Journal:  Biomed Pharmacother       Date:  1999-04       Impact factor: 6.529

2.  The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Authors:  E Ilijic; J N Guzman; D J Surmeier
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

Review 3.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

4.  Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release.

Authors:  D H Munzenmaier; D R Harder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-04       Impact factor: 4.733

Review 5.  Soluble epoxide hydrolase inhibitors: a patent review.

Authors:  Hong C Shen
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

6.  Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.

Authors:  Liu Liu; Chen Chen; Wei Gong; Yuanjing Li; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-16       Impact factor: 4.030

7.  Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages.

Authors:  Lynn Williams; Laura Bradley; Alexandra Smith; Brian Foxwell
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

Review 8.  Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer.

Authors:  Guodong Zhang; Sean Kodani; Bruce D Hammock
Journal:  Prog Lipid Res       Date:  2013-12-15       Impact factor: 16.195

Review 9.  Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies.

Authors:  Emilio Fernandez-Espejo
Journal:  Mol Neurobiol       Date:  2004-02       Impact factor: 5.590

10.  Activation of TRPV1 prevents OxLDL-induced lipid accumulation and TNF-α-induced inflammation in macrophages: role of liver X receptor α.

Authors:  Jin-Feng Zhao; Li-Chieh Ching; Yu Ru Kou; Shing-Jong Lin; Jeng Wei; Song-Kun Shyue; Tzong-Shyuan Lee
Journal:  Mediators Inflamm       Date:  2013-06-26       Impact factor: 4.711

View more
  9 in total

Review 1.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

2.  Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development.

Authors:  Navya Lakkappa; Praveen T Krishnamurthy; Karthik Yamjala; Sung Hee Hwang; Bruce D Hammock; B Babu
Journal:  J Pharm Biomed Anal       Date:  2017-11-16       Impact factor: 3.935

3.  Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.

Authors:  Qian Ren; Min Ma; Jun Yang; Risa Nonaka; Akihiro Yamaguchi; Kei-Ichi Ishikawa; Kenta Kobayashi; Shigeo Murayama; Sung Hee Hwang; Shinji Saiki; Wado Akamatsu; Nobutaka Hattori; Bruce D Hammock; Kenji Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

Review 4.  Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.

Authors:  Karen M Wagner; Cindy B McReynolds; William K Schmidt; Bruce D Hammock
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

Review 5.  The Role of Lipids in Parkinson's Disease.

Authors:  Helena Xicoy; Bé Wieringa; Gerard J M Martens
Journal:  Cells       Date:  2019-01-07       Impact factor: 6.600

Review 6.  Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.

Authors:  Mercè Pallàs; Santiago Vázquez; Coral Sanfeliu; Carles Galdeano; Christian Griñán-Ferré
Journal:  Biomolecules       Date:  2020-05-01

Review 7.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.

Authors:  Yun Sheng; Hanyu Yang; Tong Wu; Liang Zhu; Li Liu; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

8.  Hizikia fusiforme functional oil (HFFO) prevents neuroinflammation and memory deficits evoked by lipopolysaccharide/aluminum trichloride in zebrafish.

Authors:  Ying-Ying Nie; Long-Jian Zhou; Yan-Mei Li; Wen-Cong Yang; Ya-Yue Liu; Zhi-You Yang; Xiao-Xiang Ma; Yong-Ping Zhang; Peng-Zhi Hong; Yi Zhang
Journal:  Front Aging Neurosci       Date:  2022-09-09       Impact factor: 5.702

Review 9.  Docosahexaenoic and Arachidonic Acids as Neuroprotective Nutrients throughout the Life Cycle.

Authors:  Verónica Sambra; Francisca Echeverria; Alfonso Valenzuela; Raphaël Chouinard-Watkins; Rodrigo Valenzuela
Journal:  Nutrients       Date:  2021-03-18       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.